Introduction
The concept of therapeutic angiogenesis induced by administration of angiogenic genes or proteins has been established in numerous preclinical models. 1, 2 Previously, pilot clinical trials of therapeutic angiogenesis using some of these growth factors, such as basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF), have been reported in patients with coronary artery disease. [3] [4] [5] [6] [7] Although subjective symptoms were significantly improved in these phase I and II trials, some studies failed to demonstrate significant improvement in objective findings such as myocardial perfusion and exercise tolerance. Although further studies are necessary, one might assume that induction of angiogenesis alone may not be enough to improve objective findings. Thus, we thought that other beneficial effects might be mandatory in treating patients with ischemic cardiomyopathy. Indeed, in animal models and patients with AMI, left ventricular (LV) remodeling is accompanied by the accumulation of myocardial interstitial collagen in the non-infarcted region of the heart. Currently, myocardial interstitial fibrosis in the non-infarcted region is considered to be a major histological landmark resulting in cardiac dysfunction after AMI. 8, 9 It is noteworthy that VEGF has a potent effect on angiogenesis, 3, 4, 7 but no direct effect to reduce fibrosis, whereas bFGF, a potent angiogenic growth factor, stimulates fibrosis. From this viewpoint, hepatocyte growth factor (HGF) should become the center of interest, as it is a well-known angiogenic growth factor having an antifibrotic action. As a potent angiogenic growth factor in mouse, rat and rabbit ischemia models, 4, [10] [11] [12] [13] [14] [15] the mitogenic activity of HGF has been reported to be more potent than that of VEGF or bFGF in human aortic endothelial cells in vitro as well as a rabbit hindlimb ischemia model in vivo. 4, 16 Moreover, we and other investigators have demonstrated the antifibrotic effect of HGF in various organs such as liver, 17, 18 kidney, 19 lung 20 and heart. 21, 22 Hepatocyte growth factor prevented the initiation and progression of chronic fibrosis through the inhibition of TGF-b expression in a wide variety of animal models, 18, 20, 21 resulting in blockade of myofibroblastic activation of interstitial fibroblasts. The present study demonstrated a therapeutic approach to increase new vessel formation and decrease fibrosis by means of HGF in a porcine chronic ischemic cardiomyopathy model as a new therapeutic concept. Based on the preclinical data in the porcine model and clinical trial, a phase I study to treat no-option patients with chronic angina is ongoing.
Results
In vivo transfection into myocardium using needle injection catheter Initially, we tested the possibility of transfecting human HGF plasmid DNA into porcine myocardium using the NOGA system. Consistent with previous reports, [23] [24] [25] we confirmed the expression of transgene. As shown in Figure 1 , human HGF protein could be detected both in the core and perimeter regions in a volume-dependent manner (Po0.01), whereas no human HGF protein was detected in control animals, and blood or non-targeted organs of animals tranfected with human HGF plasmid DNA (data not shown). In addition, we could also detect human HGF protein at 14 days, but not at 28 days after HGF transfer (data not shown). Electro-mapping and injection of plasmid DNA using the NOGA system were associated with transient ventricular ectopic activity, but neither sustained ventricular arrhythmias nor other arrhythmias were observed. No deaths occurred during the injection procedure or the follow-up. In consideration of a human trial, we decided to perform six injections of 0.5 ml to inject human HGF plasmid DNA into the ischemic myocardium, as fewer injections would reduce the induction of ventricular arrhythmia by penetration of the needle into the myocardium.
To transfect the ischemic area, we employed the NOGA mapping system. In all animals, NOGA maps were reliably reproduced after gene therapy in terms of the number of points, end-diastolic volume, end-systolic volume and average loop stability (data not shown). As shown in Figure 2 , the ischemic area determined by NOGA mapping before HGF transfer was not significantly different among the groups (data not shown). At 1 Gene therapy for ischemic cardiomyopathy J Azuma et al month after transfer, the ischemic area was significantly decreased in the HGF-treated group as compared with the control group in a dose-dependent manner (Po0.01). In contrast, the zone of ischemia was not different between the non-injected group and control group (data not shown). There was no significant difference in the ischemic area between animals transfected with control vector and those injected with saline (data not shown).
Effects of intramyocardial transfection of hepatocyte growth factor plasmid DNA on neovascularization Vascular endothelial cells in ischemic regions stained immunohistologically with anti-vWF antibody at 1 month after treatment (Figure 3a ). The capillary density was markedly increased in myocardium transfected with 4 mg human HGF plasmid DNA as compared to control (Po0.05; Figure 3b ). To confirm the functional changes in blood flow, regional blood flow (ml/min/g) was also measured by colored dye microspheres in the ischemic region (control: 1.470.5; 0.4 mg HGF: 1.770.6; 4 mg HGF: 2.370.6) and non-ischemic region (control: 1.770.5; 0.4 mg HGF: 1.870.5; 4 mg HGF: 1.770.7). The perfusion ratio between the ischemic and normal LV regions was significantly increased in animals transfected with human HGF plasmid DNA as compared to control, in a dose-dependent manner (Po0.01; Figure  3c ). However, selective left and right coronary angiography to evaluate collateral development before and after treatment did not demonstrate any changes in the mean Rentrop score of collateral development to the LCX territory from baseline (data not shown).
To evaluate the beneficial effects of HGF gene therapy, we measured cardiac function. To assess ejection fraction (EF), we employed two independent measurements using the NOGA system and echocardiography before and after treatment. There was a significant correlation between EF evaluated by the NOGA system and echocardiography (r ¼ 0.86, Po0.01), suggesting the accuracy of NOGA analysis. Ejection fraction determined by NOGA mapping before HGF transfer was not different among the three groups (Figure 4a ). At 1 month after transfer, EF was significantly increased in animals transfected with 4 mg human HGF plasmid DNA as compared to control (Po0.05). Similarly, % change in EF determined by echocardiography after HGF gene therapy was also significantly increased in the 4 mg HGF group (Po0.05) (Figure 4b ). Improvement of cardiac dysfunction by HGF gene therapy was further confirmed by the regional wall motion. In this study, we measured the regional wall motion at rest and after dobutamine stress (peak dose 40 mg/kg/min). As shown in Figure 4c , % change in fractional wall thickening (FWT) in the ischemic region from baseline to after HGF gene therapy in animals transfected with 4 mg human HGF plasmid DNA was significantly increased both at rest and after dobutamine infusion, in a dose-dependent manner (Po0.05). Different from VEGF studies, 26 we did not observe pericardial effusion or tamponade using echocardiography. Overall, the present study clearly demonstrated that in vivo transfection of human HGF plasmid DNA resulted in significant improvement of cardiac dysfunction in a chronic porcine ischemia model.
Molecular mechanisms of hepatocyte growth factor gene therapy
To further elucidate the beneficial effects of HGF gene therapy in a chronic ischemia model, we focused on the antifibrotic actions of HGF. Different from VEGF and Gene therapy for ischemic cardiomyopathy J Azuma et al FGF, previous reports demonstrated that overexpression of HGF showed an antifibrotic action in various models, in addition to angiogenesis. [22] [23] [24] [25] [26] [27] As our previous studies revealed that HGF stimulated the degradation of extracellular matrix through activation of MMP-1 and uPA, and inhibited the synthesis of extracellular matrix through the inhibition of TGF-b expression, 21 we measured the fibrotic area in the myocardium after HGF gene transfection. As expected, the ischemic myocardium demonstrated a significant increase in fibrosis as compared to the normal group. Importantly, a significant decrease was observed in the myocardium of pigs transfected with human HGF vector as compared to control 1 month after transfection, in a dosedependent manner (Po0.01; Figure 5 ). Indeed, expression of collagen I and collagen III in the ischemic myocardium of animals transfected with human HGF plasmid DNA was significantly lower than that of control (Po0.01; Figure 6 ), whereas ischemic myocardium exhibited higher expression of collagen I and III mRNA as compared to non-ischemic myocardium (Po0.01). More importantly, transfection of HGF plasmid DNA resulted in a significant decrease in TGF-b mRNA expression (Po0.01; Figure 6b ). These results demonstrate that the angiogenic and antifibrotic actions induced by gene transfer of HGF would be beneficial in treating chronic ischemia. Of note, human HGF could not be detected in plasma 3 days, 1, 2 and 4 weeks after transfection. Therefore, the alteration of cardiac structure seemed to be due to local effects of HGF.
Discussion
The concept of therapeutic angiogenesis induced by administration of angiogenic genes or proteins has been established in numerous preclinical models.
1,2 Recently, pilot clinical trials of therapeutic angiogenesis using some of these growth factors such as bFGF or VEGF have been reported in patients with coronary artery disease. [3] [4] [5] [6] [7] Although subjective symptoms were significantly improved in these phase I or II trials, some studies failed to demonstrate significant improvement in objective findings such as myocardial perfusion and exercise tolerance. Gene therapy for ischemic cardiomyopathy J Azuma et al the lack of other properties, as these growth factors have only an angiogenic property, whereas chronic ischemia involves various factors including remodeling. Indeed, bFGF stimulated rather than reduced the fibrosis, whereas VEGF did not have a direct effect to reduce fibrosis. From this view point, HGF should be the center of interest, as it is an antifibrotic and angiogenic growth factor.
In this study, transfection of human HGF plasmid DNA significantly improved the blood flow, accompanied by a significant increase in capillary density in the ischemic lesion at 1 month after transfection. The angiogenic activity of HGF has been reported to be more potent than that of VEGF or bFGF in human aortic endothelial cells in vitro and in vivo. 4, 16 In addition, there was no evidence of edema in patients with critical limb ischemia transfected with the human HGF gene, 28 in marked contrast to a VEGF trial in which 60% of patients developed moderate or severe edema in a phase I/IIa trial. 26 The present study also confirmed a large difference in causing pericardial effusion in the treatment of myocardial ischemia. The lack of effect of HGF to induce edema is considered to be a distinguishing feature of HGF due to stimulation of the migration of vascular smooth muscle cells (VSMC) without the replication of VSMC, whereas VEGF does not stimulate either the migration or proliferation of VSMC. 29 With an absence of pericardial effusion, this study exhibited a significant improvement of cardiac dysfunction by HGF gene therapy as assessed by the NOGA system and echocardiography. The changes in cardiac function by HGF seem to be sufficient to be applicable for the treatment of human patients.
One of unique beneficial functions of HGF is that HGF transfer inhibited cardiac fibrosis, accompanied by inhibition of collagen I, III and TGF-b expression. Consistent with the present study, we and others reported an antifibrotic effect of HGF on various organs such as the liver, 17, 18 kidney, 19 lung 20 and heart. 21, 22 Many factors are known to regulate the fibrogenic process after tissue injury, in which TGF-b is believed to be the principal factor playing a central role. Hepatocyte growth factor prevents the initiation and progression of chronic fibrosis through the inhibition of TGF-b expression in a wide variety of animal models. 18, 20, 21 Recently, Mizuno et al. 20 demonstrated that HGF promoted apoptosis of myofibroblasts, which produce much TGFb in pathological conditions, resulting in inhibition of expression of TGF-b in the fibrotic lung. In addition, HGF has been reported to abolish TGF-b induction, 20, 21 and also intercept TGF-b-initiated Smad signaling 30, 31 in interstitial fibroblasts. Hepatocyte growth factor attenuated the translocation to and accumulation of activated Smad-2/3 in the nucleus, dependent on Erk-1/2 phosphorylation, 30 and also induced the expression of decorin, which can bind to active TGF-b and sequester its actions. 31 Together with these data, HGF inhibited TGF-b pro-fibrotic signaling by the downregulation of TGF-b itself, and intercepted its transition even in the myocardium. The antifibrotic actions of HGF depend on (1) inhibition of collagen synthesis through inhibition of TGF-b expression and (2) degradation of collagen through activation of MMP-1 and uPA, etc.
Overall, the present studies suggest a novel therapeutic strategy that might reduce the symptoms of ischemic myocardial infarction, utilizing the angiogenic and antifibrotic properties of HGF gene transfer. In addition, the stimulation of new vessel formation and decrease in cardiac fibrosis by HGF are likely to create new therapeutic options in fibrotic conditions such as cardiomyopathy, chronic heart failure and pulmonary fibrosis.
Recently, we performed a human clinical phase I/IIa trial to treat the patients with lower limb ischemia. This study, despite being a single-center open-label trial, demonstrated that intramuscular injection of naked Gene therapy for ischemic cardiomyopathy J Azuma et al HGF plasmid was safe, feasible, and could achieve successful improvement of ischemic limbs. 28 Nevertheless, the clinical utility of gene therapy in the myocardium is still unclear. Currently, a phase I study of HGF gene therapy using a needle injection catheter to treat no-option patients with chronic angina is ongoing.
Materials and methods

Chronic ischemia model and gene transfer
Twenty-eight male pigs weighing 25-30 kg (KAC, Co. Ltd, Kyoto, Japan) were used to examine the angiogenic and antifibrotic effects of human HGF plasmid (phHGF). 28 To induce chronic myocardial ischemia, an ameroid constrictor (Research Instruments NW, Inc., Lebanon, OR, USA) was placed around the proximal portion of the left circumflex coronary artery (LCx) after left thoracotomy, as previously described. 32 Before and at 1 month after gene transfer, all pigs underwent selective coronary angiography, dobutamine stress echocardiography (DSE) and NOGA LV electromechanical mapping (EMM; Cordis, FL, USA). 3 Myocardial viability was evaluated by unipolar (UpV) and bipolar endocardial potential, and local functional analysis was performed by linear local shortening (LLS). Areas of ischemia were defined as those with preserved UpV (46 mV viable myocardium) and impaired LLS (o12% decreased contractility). We excluded seven pigs because four pigs died just after ischemia, two pigs died within 1 month after ischemia and the coronary occlusion of one pig was insufficient. Immediately after identification of total coronary occlusion by cinecoronariography and the ischemic territory by EMM, 0.4 (n ¼ 6) or 4 mg (n ¼ 6) phHGF in 3 ml saline or control vector (control group, n ¼ 6) was randomly selected and injected into six independent sites within the ischemic myocardium (0.5 ml to each site) using a NOGA injection catheter (MyoSTAR) (Cordis, FL, USA) at 1 month after the treatment of ameroid constrictor. A cardiologist unaware of treatment group assignment interpreted the echocardiography and NOGA measurements. After we stopped the hearts of animals in diastole by intravenous KCl (10 ml/kg) infusion, myocardial samples were collected for histological or real-time RT-PCR analysis. All analyses were performed in a blinded manner. This animal experiment was approved by the Animal Care Committee of Osaka University.
Effect of injection volume on transduction efficiency
To examine gene expression, phHGF administration was performed in three healthy, non-ischemic pigs. To inject 4 mg phHGF effectively, three different methods (15 injections: 0.1 ml each; 10 injections: 0.2 ml each; six injections: 0.5 ml each) were designed. These doses and volumes corresponded to a dose and volume of 267 mg in 0.1 ml, 0.4 mg in 0.2 ml and 667 mg in 0.5 ml, respectively. In this study, the LV wall of the three pigs was exposed, and phHGF was injected in each animal. Each injection site was spaced at least 1 cm apart. An epicardial 6-0 nylon suture was placed at each injection site for marking. The animals were killed at 4 days after injections. Tissue samples were collected, extracted and HGF protein was quantified by ELISA. Each tissue sample comprised a core sample (8 mm circumference around the injection site) and a perimeter sample (2 mm circumference from the core circumference to the edge of the sample).
Echocardiography
Transthoracic echocardiography (SONOS 5500, Philips Medical Systems, Andover, MA, USA) was performed just before and 1 month after HGF transfer, as described previously. 32, 33 Ejection fraction and FWT were quantified using the LV short-axis view at the midpapillary muscle level. Dobutamine stress echocardiography was performed at baseline and follow-up in B3-min stages with incremental doses of dobutamine beginning with B5 mg/kg/min and increased to 40 mg/kg/min. 34 Regional wall motion was evaluated by dividing the left ventricle into four equal 901 radial segments; these consisted of the ischemic region (lateral wall), two adjacent ischemic regions (anterior and posterior walls) and a remote ischemic region (septal wall). Fractional wall thickening was defined as mean systolic wall thickening Â 100/mean diastolic wall thickness, and calculated at rest and peak stress.
Coronary angiography
Coronary angiography was performed on all animals before and after treatment. Collateral flow to the LCx territory was graded angiographically in a blinded fashion with the Rentrop scoring system. 35 Evaluation of angiograms was performed through cine review by a blinded experienced angiographer.
Regional myocardial perfusion
The perfusion ratio between the ischemic and normal LV regions was calculated at rest by use of colored microspheres injected near the mitral valve. 36 After killing, a transmural myocardial tissue sample approximately 1 cm thick was cut from the ischemic (LCx territory) after tissue perfusion fixation.
Histological assessment
All pigs were killed at 1 month after HGF transfer. Using samples of myocardium fixed with 4% PFA, immunohistochemical staining was performed to evaluate the blood vessels using rabbit antihuman von Willebrand factor antibody (1:400; Sigma, St Louis, MO, USA). To determine the extent of neovascularization in the collateral-dependent and normal areas of the myocardium histologically, the number of capillary was scored by an investigator blinded to the nature of specimens, in four randomly chosen fields ( Â 200 magnification) in six sections from ischemic myocardium (LCx) in both groups of animals, and the results were expressed as number of vessels/mm 2 . For collagen staining, Sirius red staining was employed. Sections of heart 5-mm thick were placed on slides, deparaffinized and incubated with a saturated solution of picric acid containing 0.1% Sirius red.
Total RNA extraction and real-time PCR Samples of myocardium from the ischemic and nonischemic areas were taken at 1 month after injections using the NOGA system. Total RNA was isolated from the myocardium of the ischemic and normal LV regions using PURESCRIPT RNA Purification (Gentra Systems, Minneapolis, MN, USA) as described previously. 37 Complementary DNA (cDNA) was synthesized from 
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Statistical analysis
All values are expressed as mean7s.e.m. ANOVA with subsequent Dunnett's test was used to determine the significance of differences in multiple comparisons. Differences of Po0.05 were considered significant.
